Watch EDSA. Know when insiders buy.
One email the day a filing lands. Free.
EDSA
Edesa Biotech, Inc.
4.23
−0.43 −9.23%
USD · close Sep 11
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
59
WATCH · shorts 59
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $40.8MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$14.1MNET CASH —52W 0.80 – 18.28SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2026 · Jun 30 | — | — | — | −$5.5M | −$5.4M | — | -0.60 | −$3.1M | — | — | Aug 13 |
| Q2 2026 · Mar 31 | — | — | — | −$4.3M | −$4.2M | — | -0.49 | −$2M | — | — | May 14 |
| Q1 2026 · Dec 31 | — | — | — | −$2.3M | −$2.2M | — | -0.28 | −$2.1M | — | — | Feb 13 |
| Q4 2025 · Sep 30derived | — | — | — | −$2.5M | −$2.2M | — | -0.32 | −$1.7M | — | — | Dec 12 |
| Q3 2025 · Jun 30 | — | — | — | −$1.9M | −$1.7M | — | -0.25 | −$1.7M | — | — | Aug 13 |
| Q2 2025 · Mar 31 | — | — | — | −$1.6M | −$1.6M | — | -0.30 | −$2.4M | — | — | May 14 |
| Q1 2025 · Dec 31 | — | — | — | −$1.9M | −$1.6M | — | -0.48 | −$1.5M | — | — | Feb 13 |
| Q4 2024 · Sep 30derived | — | — | — | −$1M | −$962K | — | -0.29 | −$967K | — | — | Dec 12 |
| Q3 2024 · Jun 30 | — | — | — | −$1.9M | −$1.7M | — | -0.52 | −$856K | — | — | Aug 8 |
| Q2 2024 · Mar 31 | — | — | — | −$2.2M | −$1.9M | — | -0.58 | −$1.7M | — | — | May 14 |
| Q1 2024 · Dec 31 | — | — | — | −$1.9M | −$1.7M | — | -0.54 | −$1.4M | — | — | Feb 14 |
| Q4 2023 · Sep 30derived | — | — | — | −$2.4M | −$1.7M | — | -0.56 | −$1.5M | $0 | −$1.5M | Dec 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Sep 30 | — | — | −$7.9M | −$7.2M | — | -1.27 | −$7.3M | — | — | — | — |
| FY2024 · to Sep 30 | — | — | −$7M | −$6.2M | — | -1.93 | −$4.9M | — | — | — | — |
| FY2023 · to Sep 30 | — | — | −$9.2M | −$8.4M | — | -2.93 | −$6.6M | $0 | −$6.6M | — | — |
| FY2022 · to Sep 30 | — | — | −$18.4M | −$17.5M | — | — | −$12.3M | $6K | −$12.3M | — | — |
| FY2021 · to Sep 30 | $0 | — | −$23.7M | −$13.3M | — | -1.10 | −$13.7M | $6K | −$13.7M | — | — |
| FY2020 · to Sep 30 | $329K | 94.6% | −$6.4M | −$6.4M | -1935.3% | -0.74 | −$5M | $5K | −$5M | — | — |
Every number comes from Edesa Biotech, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.